Shihui Ling
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Shihui Ling has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Bin Guo
Shandong University of Traditional Chinese Medicine, Jinan, China
2 shared publications - Hongsheng Bi
Affiliated Eye Hospital of Shandong University of Traditional Chinese Medicine
2 shared publications - Jingyi Yang
Medical College of Optometry and Ophthalmology, Shandong University of Traditional Chinese Medicine, Jinan, 250355, PR China
2 shared publications Qifeng Ye
Medical College of Optometry and Ophthalmology, Shandong University of Traditional Chinese Medicine, Jinan, 250355, PR China
2 shared publicationsXiaomeng Li
Medical College of Optometry and Ophthalmology, Shandong University of Traditional Chinese Medicine, Jinan, 250355, PR China
2 shared publicationsXiaotong Shao
Medical College of Optometry and Ophthalmology, Shandong University of Traditional Chinese Medicine, Jinan, 250355, PR China
2 shared publications
Latest Publications
- 28 July 2026
- Published by Elsevier in Phytomedicine
- Vol. 160, 158647
Gasdermin D regulates choroidal blood flow and axial elongation in high myopia and therapeutic potential of apigenin
- 28 July 2026
- Published by Elsevier in Phytomedicine
- Vol. 160, 158647
Gasdermin D regulates choroidal blood flow and axial elongation in high myopia and therapeutic potential of apigenin
- Open Access
- 3 May 2026
- Published by Elsevier in SSRN Electronic Journal
GSDMD Regulates Choroidal Blood Flow and Axial Elongation in High Myopia and Therapeutic Potential of Apigenin
Despite advancements in treatments like atropine, pathological changes in high myopia (HM) still lead to vision loss, necessitating novel therapeutic targets. Clinically, axial elongation and refraction decrease are closely associated with reduced choroidal blood flow. This study identified GSDMD, a pyroptosis-related protein, as a critical regulator in HM. Researches demonstrated that chemical inhibition of GSDMD significantly mitigated axial elongation, refractive shifts, and choroidal blood flow reduction. Furthermore, by screening traditional Chinese medicine pharmacological activity, we identified Artemisia argyi and its active component, apigenin, as effective GSDMD inhibitors that mimic the protective effects of chemical inhibition. In summary, our study systematically elucidates the role of GSDMD-mediated pyroptosis in the progression of high myopia. By identifying the apigenin-GSDMD axis as a key modulator of choroidal hemodynamics and axial growth, we provide a novel therapeutic strategy and a theoretical basis for pharmacological intervention in high myopia.
- 3 May 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessGSDMD Regulates Choroidal Blood Flow and Axial Elongation in High Myopia and Therapeutic Potential of Apigenin
Despite advancements in treatments like atropine, pathological changes in high myopia (HM) still lead to vision loss, necessitating novel therapeutic targets. Clinically, axial elongation and refraction decrease are closely associated with reduced choroidal blood flow. This study identified GSDMD, a pyroptosis-related protein, as a critical regulator in HM. Researches demonstrated that chemical inhibition of GSDMD significantly mitigated axial elongation, refractive shifts, and choroidal blood flow reduction. Furthermore, by screening traditional Chinese medicine pharmacological activity, we identified Artemisia argyi and its active component, apigenin, as effective GSDMD inhibitors that mimic the protective effects of chemical inhibition. In summary, our study systematically elucidates the role of GSDMD-mediated pyroptosis in the progression of high myopia. By identifying the apigenin-GSDMD axis as a key modulator of choroidal hemodynamics and axial growth, we provide a novel therapeutic strategy and a theoretical basis for pharmacological intervention in high myopia.